Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FHKV0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,792
Award facts
- Contract value 100% obligated
- $15,792.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $15,792.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for XOLAIR 150 mg/ml syringes. The award, issued on January 7, 2026, with an ultimate completion date of January 29, 2026, was made without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical products and medical consumables to support Department of Defense healthcare operations globally.
DMS Pharmaceutical Group has established itself as a critical pharmaceutical supplier within the federal military medical system, with substantial performance across diverse product categories including biologics, specialty pharmaceuticals, and routine medications. The company's product portfolio encompasses branded and generic prescription drugs, over-the-counter medications, vaccines, and medical consumables, positioning it to fulfill the specialized pharmaceutical requirements of DOD healthcare facilities worldwide. The PPV-G GEN V IDC (contract SPE2DR), awarded on November 13, 2025, with a $499,999,999 ceiling and completion date of December 31, 2036, features a 30-month base period with three 30-month option periods, establishing DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting recurring military medical supply needs.
Quick answers
Who was awarded contract SPE2DR26FHKV0?
SPE2DR26FHKV0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26FHKV0 worth?
The government has obligated $15,792 on SPE2DR26FHKV0.
Is contract SPE2DR26FHKV0 an order under another contract?
Yes. SPE2DR26FHKV0 is a delivery order under SPE2DR25D9222, an indefinite delivery contract.
Was contract SPE2DR26FHKV0 competed?
The extent of competition for SPE2DR26FHKV0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award